FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with immunogenic composition, which contains combination of the following parts: (i) polymerase part, which contains at least 450 amino acid residues of polymerase protein, obtained from first HBV-virus; (ii) core part, which contains at least 100 amino acid residues of heart-shaped protein, obtained from second HBV-virus; and (iii) envelope part, which contains one or more immunogenic area from 20-100 successive amino acid residues of HBsAg protein, obtained from third HBV-virus; or combination of nucleic acid molecules, coding said polymerase part, said core part and said envelope part. Group of inventions also deals with nucleic acid molecule for stimulation or increase of immune response to HBV; vector for stimulation or increase of immune response to HBV, containing one or more nucleic acid molecule; infectious viral particle for stimulation or increase of immune response to HBV; method of treatment or prevention of HBV-infections or HBV-associated disease or pathological condition; set for application in treatment of HBV-infection.
EFFECT: group of inventions ensures stability and preservation of high immunogenicity of vectors, applied in composition.
51 cl, 7 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
MUTANT POLYMERASES OF HEPATITIS B VIRUS | 2012 |
|
RU2625021C2 |
VECTORS FOR MULTIPLE GENE EXPRESSION | 2008 |
|
RU2462513C2 |
HYBRIDISATION OF HETEROOLIGOMER MYCOBACTERIAL ANTIGENS | 2015 |
|
RU2695462C2 |
IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2648791C2 |
PAPILLOMAVIRUS E2 POLYPEPTIDES USED FOR VACCINATION | 2008 |
|
RU2482189C2 |
IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
SET OF CONSERVATIVE EPITOPES OF VIRAL PROTEINS, METHOD OF THEIR IDENTIFICATION AND SELECTION, VACCINE COMPOSITION AND METHOD OF VACCINATION | 2022 |
|
RU2814020C2 |
ANTIGEN TAU-PEPTIDES AND THEIR APPLICATION | 2010 |
|
RU2518291C2 |
PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
USING MVA (MODIFIED VACCINIA ANKARA) FOR TREATING PROSTATE CANCER | 2008 |
|
RU2499606C2 |
Authors
Dates
2015-07-10—Published
2010-08-06—Filed